Evaluation of PPARγ agonists on rodent endothelial cell proliferation

Satoko Kakiuchi-Kiyota, Lora L Arnold, Masanao Yokohira, Shugo Suzuki, Karen L. Pennington, Samuel Monroe Cohen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The PPARγ agonist troglitazone (TG) induced an increased incidence of hemangiosarcomas in mice but was not carcinogenic in rats. In contrast, pioglitazone (PIO) did not induce hemangiosarcomas or any other tumors in mice. We previously demonstrated that TG increased the proliferation of endothelial cells (ECs) in liver and adipose tissue in mice, and acted as a mitogenic stimulant and an inhibitor of apoptosis in vitro in mouse, but not human, ECs. In the present study, we investigated whether TG had any effect on the proliferation of ECs in rats. We also evaluated the in vivo and in vitro effects of PIO on ECs in mice. In rats, TG did not increase the Ki-67 labeling index (LI) of ECs in liver or adipose tissue at doses used in the two-year bioassay, and did not increase hepatocyte proliferation. PIO administered to mice did not increase the Ki-67 LI of hepatocytes or ECs in liver or white adipose tissue, but slightly increased the EC proliferation in brown adipose tissue. PIO was slightly mitogenic on cultured mouse ECs after 3 days of treatment but not after 6 days, and there was no inhibition of apoptosis, in contrast to what was seen with TG. The data support the conclusion that sustained EC proliferation in mice is necessary, for the induction of hemangiosarcomas by TG, and these short-term and long-term effects are not seen with TG in the rat or with PIO in mice, treatments that also are not related to the induction of hemangiosarcomas in two-year bioassays.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalToxicology
Volume287
Issue number1-3
DOIs
StatePublished - Sep 5 2011

Fingerprint

troglitazone
pioglitazone
Peroxisome Proliferator-Activated Receptors
Endothelial cells
Cell proliferation
Rodentia
Endothelial Cells
Cell Proliferation
Hemangiosarcoma
Rats
Liver
Tissue
Bioassay
Biological Assay
Labeling
Adipose Tissue
Hepatocytes
Apoptosis
White Adipose Tissue
Brown Adipose Tissue

Keywords

  • Endothelial cell proliferation
  • Hemangiosarcoma
  • PPARγ agonist
  • Pioglitazone
  • Rodent
  • Troglitazone

ASJC Scopus subject areas

  • Toxicology

Cite this

Evaluation of PPARγ agonists on rodent endothelial cell proliferation. / Kakiuchi-Kiyota, Satoko; Arnold, Lora L; Yokohira, Masanao; Suzuki, Shugo; Pennington, Karen L.; Cohen, Samuel Monroe.

In: Toxicology, Vol. 287, No. 1-3, 05.09.2011, p. 91-98.

Research output: Contribution to journalArticle

Kakiuchi-Kiyota, S, Arnold, LL, Yokohira, M, Suzuki, S, Pennington, KL & Cohen, SM 2011, 'Evaluation of PPARγ agonists on rodent endothelial cell proliferation', Toxicology, vol. 287, no. 1-3, pp. 91-98. https://doi.org/10.1016/j.tox.2011.05.019
Kakiuchi-Kiyota, Satoko ; Arnold, Lora L ; Yokohira, Masanao ; Suzuki, Shugo ; Pennington, Karen L. ; Cohen, Samuel Monroe. / Evaluation of PPARγ agonists on rodent endothelial cell proliferation. In: Toxicology. 2011 ; Vol. 287, No. 1-3. pp. 91-98.
@article{889e605636a6415d868d8a326fd2aa5f,
title = "Evaluation of PPARγ agonists on rodent endothelial cell proliferation",
abstract = "The PPARγ agonist troglitazone (TG) induced an increased incidence of hemangiosarcomas in mice but was not carcinogenic in rats. In contrast, pioglitazone (PIO) did not induce hemangiosarcomas or any other tumors in mice. We previously demonstrated that TG increased the proliferation of endothelial cells (ECs) in liver and adipose tissue in mice, and acted as a mitogenic stimulant and an inhibitor of apoptosis in vitro in mouse, but not human, ECs. In the present study, we investigated whether TG had any effect on the proliferation of ECs in rats. We also evaluated the in vivo and in vitro effects of PIO on ECs in mice. In rats, TG did not increase the Ki-67 labeling index (LI) of ECs in liver or adipose tissue at doses used in the two-year bioassay, and did not increase hepatocyte proliferation. PIO administered to mice did not increase the Ki-67 LI of hepatocytes or ECs in liver or white adipose tissue, but slightly increased the EC proliferation in brown adipose tissue. PIO was slightly mitogenic on cultured mouse ECs after 3 days of treatment but not after 6 days, and there was no inhibition of apoptosis, in contrast to what was seen with TG. The data support the conclusion that sustained EC proliferation in mice is necessary, for the induction of hemangiosarcomas by TG, and these short-term and long-term effects are not seen with TG in the rat or with PIO in mice, treatments that also are not related to the induction of hemangiosarcomas in two-year bioassays.",
keywords = "Endothelial cell proliferation, Hemangiosarcoma, PPARγ agonist, Pioglitazone, Rodent, Troglitazone",
author = "Satoko Kakiuchi-Kiyota and Arnold, {Lora L} and Masanao Yokohira and Shugo Suzuki and Pennington, {Karen L.} and Cohen, {Samuel Monroe}",
year = "2011",
month = "9",
day = "5",
doi = "10.1016/j.tox.2011.05.019",
language = "English (US)",
volume = "287",
pages = "91--98",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Evaluation of PPARγ agonists on rodent endothelial cell proliferation

AU - Kakiuchi-Kiyota, Satoko

AU - Arnold, Lora L

AU - Yokohira, Masanao

AU - Suzuki, Shugo

AU - Pennington, Karen L.

AU - Cohen, Samuel Monroe

PY - 2011/9/5

Y1 - 2011/9/5

N2 - The PPARγ agonist troglitazone (TG) induced an increased incidence of hemangiosarcomas in mice but was not carcinogenic in rats. In contrast, pioglitazone (PIO) did not induce hemangiosarcomas or any other tumors in mice. We previously demonstrated that TG increased the proliferation of endothelial cells (ECs) in liver and adipose tissue in mice, and acted as a mitogenic stimulant and an inhibitor of apoptosis in vitro in mouse, but not human, ECs. In the present study, we investigated whether TG had any effect on the proliferation of ECs in rats. We also evaluated the in vivo and in vitro effects of PIO on ECs in mice. In rats, TG did not increase the Ki-67 labeling index (LI) of ECs in liver or adipose tissue at doses used in the two-year bioassay, and did not increase hepatocyte proliferation. PIO administered to mice did not increase the Ki-67 LI of hepatocytes or ECs in liver or white adipose tissue, but slightly increased the EC proliferation in brown adipose tissue. PIO was slightly mitogenic on cultured mouse ECs after 3 days of treatment but not after 6 days, and there was no inhibition of apoptosis, in contrast to what was seen with TG. The data support the conclusion that sustained EC proliferation in mice is necessary, for the induction of hemangiosarcomas by TG, and these short-term and long-term effects are not seen with TG in the rat or with PIO in mice, treatments that also are not related to the induction of hemangiosarcomas in two-year bioassays.

AB - The PPARγ agonist troglitazone (TG) induced an increased incidence of hemangiosarcomas in mice but was not carcinogenic in rats. In contrast, pioglitazone (PIO) did not induce hemangiosarcomas or any other tumors in mice. We previously demonstrated that TG increased the proliferation of endothelial cells (ECs) in liver and adipose tissue in mice, and acted as a mitogenic stimulant and an inhibitor of apoptosis in vitro in mouse, but not human, ECs. In the present study, we investigated whether TG had any effect on the proliferation of ECs in rats. We also evaluated the in vivo and in vitro effects of PIO on ECs in mice. In rats, TG did not increase the Ki-67 labeling index (LI) of ECs in liver or adipose tissue at doses used in the two-year bioassay, and did not increase hepatocyte proliferation. PIO administered to mice did not increase the Ki-67 LI of hepatocytes or ECs in liver or white adipose tissue, but slightly increased the EC proliferation in brown adipose tissue. PIO was slightly mitogenic on cultured mouse ECs after 3 days of treatment but not after 6 days, and there was no inhibition of apoptosis, in contrast to what was seen with TG. The data support the conclusion that sustained EC proliferation in mice is necessary, for the induction of hemangiosarcomas by TG, and these short-term and long-term effects are not seen with TG in the rat or with PIO in mice, treatments that also are not related to the induction of hemangiosarcomas in two-year bioassays.

KW - Endothelial cell proliferation

KW - Hemangiosarcoma

KW - PPARγ agonist

KW - Pioglitazone

KW - Rodent

KW - Troglitazone

UR - http://www.scopus.com/inward/record.url?scp=79960700881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960700881&partnerID=8YFLogxK

U2 - 10.1016/j.tox.2011.05.019

DO - 10.1016/j.tox.2011.05.019

M3 - Article

C2 - 21684317

AN - SCOPUS:79960700881

VL - 287

SP - 91

EP - 98

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 1-3

ER -